{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19","upperLimit":"33","value":"26"}]}],"title":"Grades II-IV"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4","upperLimit":"14","value":"9"}]}],"title":"Grades III-IV"}],"denoms":[{"counts":[{"groupId":"OG000","value":"156"}],"units":"Participants"}],"description":"Incidence and severity of GVHD will be scored according to the BMT clinical trials network Manual of Procedures.","dispersionType":"95% Confidence Interval","groups":[{"description":"Autologous transplant plus non-myeloablative allogeneic transplant for standard risk patients","id":"OG000","title":"Auto-Allo Standard Risk"}],"paramType":"NUMBER","populationDescription":"GVHD was only assessed on the Auto-Allo arm for standard risk patients that completed second transplant","reportingStatus":"POSTED","timeFrame":"Day 100","title":"Incidences of Graft Versus Host Disease (GVHD)","type":"SECONDARY","unitOfMeasure":"percentage of patients"}